Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brexpiprazole in agitation associated with Alzheimer's dementia
NCT01922258Phase 3Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Sep 2013
- Primary completion
- Mar 2017
- Modality
- Small Molecules
- Countries
- 9
01
Overview
A Phase 3 trial of brexpiprazole in Alzheimer's disease (AD), sponsored by Otsuka Pharmaceutical Development & Commercialization. Started Sep 2013; status: completed.
02
Drugs
brexpiprazole
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT01922258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01922258.